(Q85041651)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence! (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Peter Borchmann

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Andreas Engert

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Volker Diehl

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

4 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

636-637

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.149

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.149

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.149

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.149

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.149

The past: what we have learned in the last decade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.149

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.149

Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.149

10.1038/NRCLINONC.2011.149

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21971592%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference